Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Tirzepatide (Zepbound for weight loss, Mounjaro for diabetes) achieved 22.5% average weight loss in SURMOUNT-1, the Phase 3 trial that earned its FDA approval
Despite aggressive standard of care prompting surgical resection, radiotherapy and chemotherapy, the five year survival has stagnated at around 7.2% [5,6,7]
Not for Diagnostic or Therapeutic Applications
If you face any issue, feel free to contact us
Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB
US$ 25.99
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
US$ 20.63
US$ 21.64
US$ 29.89
